Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of chronic kidney disease (CKD)
3.2.1.2 Advancements in drug formulations
3.2.1.3 Increasing incidence of cancer
3.2.1.4 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of drugs
3.2.2.2 Potential side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Biosimilars
5.3 First-generation formulation
5.4 Second-generation formulation
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Epoetin-alfa
6.3 Epoetin-beta
6.4 Darbepoetin-alfa
6.5 Other drug classes
Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Cancer
7.3 Renal diseases
7.4 Neurology
7.5 Hematology
7.6 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AstraZeneca PLC
10.2 Amgen, Inc.
10.3 Biocon Limited
10.4 Celltrion, Inc.
10.5 Dr. Reddy’s Laboratories Ltd.
10.6 F. Hoffmann-La Roche Ltd.
10.7 Intas Pharmaceuticals Ltd.
10.8 Johnson & Johnson
10.9 Kyowa Kirin Co., Ltd.
10.10 LG Chem, Ltd.
10.11 Novartis AG
10.12 Pfizer Inc.
10.13 Sanofi
10.14 Sun Pharmaceutical Industries Ltd.
10.15 Teva Pharmaceutical Industries Ltd.
